AVITA Medical (RCEL) Net Income towards Common Stockholders (2018 - 2026)

AVITA Medical (RCEL) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$1.4 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders rose 87.83% year-over-year to -$1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$38.4 million (up 37.94% YoY) and the FY2025 annual result came in at -$38.4 million, up 37.94% from the prior year.
• Net Income towards Common Stockholders improved to -$1.4 million in Q4 2025, from -$13.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $21.4 million in Q4 2022 to a low of -$18.7 million in Q1 2024.
• A 5-year average of -$9.0 million and a median of -$10.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 133.0% — and 2025, when it surged 87.83%.
• Tracing RCEL's Net Income towards Common Stockholders over 5 years: stood at -$16.7 million in 2021, then jumped by 228.49% to $21.4 million in 2022, then slumped by 133.0% to -$7.1 million in 2023, then tumbled by 63.85% to -$11.6 million in 2024, then surged by 87.83% to -$1.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$1.4 million (Q4 2025), -$13.2 million (Q3 2025), and -$9.9 million (Q2 2025), per Business Quant data.